Sarepta Therapeutics (NASDAQ: SRPT) September and October 43 calls are active after a post to the website of the FDA indicated that the regulator granted approval for eteplirsen, the company's treatment of Duchenne muscular dystrophy.

Options Trader Talk

Sarepta (SRPT) Wins Key PTO Decision on Composition of Matter Patents - OppenheimerSeptember 20, 2016 1:18 PM Sarepta Therapeutic (SRPT) PT Raised to $66 at WedbushSeptember 20, 2016 7:21 AM Sarepta Therapeutic (SRPT) PT Raised to $81 at Needham & CompanySeptember 19, 2016 1:37 PM Leerink Partners Upgrades Sarepta Therapeutic (SRPT) to Market PerformSeptember 19, 2016 1:29 PM Sarepta (SRPT) PT Raised to $76 at Oppenheimer Amid Eteplirsen ApprovalSeptember 19, 2016 1:08 PM Sarepta Therapeutics (SRPT) Pushes to Highs Following FDA Approval; +90%September 19, 2016 11:21 AM Sarepta Therapeutic (SRPT) Label More Inclusive Than Anticipated - OppenheimerSeptember 19, 2016 10:40 AM